At the 2025 VEITHsymposium in New York, Prof. Dr. Horst Sievert presented new clinical insights into the expanding field of multiorgan denervation — a novel endovascular approach that targets sympathetic overactivity across multiple organs involved in cardiovascular and metabolic diseases.
Sympathetic hyperactivity contributes to hypertension, type 2 diabetes, metabolic syndrome, heart failure, and pulmonary hypertension. Several organs — including the kidneys, liver, pancreas, duodenum, the splanchnic circulation, and the pulmonary arteries — are richly innervated and represent promising targets for catheter-based neuromodulation.
Key clinical insights:
- First-in-human experience combining renal and hepatic denervation (MODUS trial) showed meaningful reductions in blood pressure and HbA1c at 90 days.
- Multiorgan Denervation (MDN) technology using a centering balloon and three micro-needles enables targeted perivascular ethanol microinjections (Sympathol™).
- The NECTAR IV study demonstrated improvements in 24-hour ambulatory blood pressure and HbA1c in patients with both hypertension and type 2 diabetes.
- Greater splanchnic nerve denervation has shown benefits in early studies in HFpEF, including improved hemodynamics, exercise capacity, and quality of life.
- Pulmonary artery denervation has produced consistent positive results across multiple first-in-human and randomized trials in various forms of pulmonary hypertension.
Conclusion
Multiorgan denervation represents a promising new direction in interventional neuromodulation, offering potential benefits across a wide range of cardiovascular and metabolic conditions driven by sympathetic overactivity. As device technologies and clinical experience continue to evolve, multiorgan denervation is poised to become a significant therapeutic option in the coming years.
Contact for collaborations and research inquiries:
Prof. Dr. Horst Sievert
CVC Frankfurt – CardioVasculäres Centrum Frankfurt
HorstSievertMD@aol.com